These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 1314165)

  • 1. p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer.
    Unger T; Nau MM; Segal S; Minna JD
    EMBO J; 1992 Apr; 11(4):1383-90. PubMed ID: 1314165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The p53 activation domain binds the TATA box-binding polypeptide in Holo-TFIID, and a neighboring p53 domain inhibits transcription.
    Liu X; Miller CW; Koeffler PH; Berk AJ
    Mol Cell Biol; 1993 Jun; 13(6):3291-300. PubMed ID: 8497252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncogenic forms of p53 inhibit p53-regulated gene expression.
    Kern SE; Pietenpol JA; Thiagalingam S; Seymour A; Kinzler KW; Vogelstein B
    Science; 1992 May; 256(5058):827-30. PubMed ID: 1589764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of p53 mutants for transcriptional activity.
    Raycroft L; Schmidt JR; Yoas K; Hao MM; Lozano G
    Mol Cell Biol; 1991 Dec; 11(12):6067-74. PubMed ID: 1944276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 amino acids 339-346 represent the minimal p53 repression domain.
    Hong TM; Chen JJ; Peck K; Yang PC; Wu CW
    J Biol Chem; 2001 Jan; 276(2):1510-5. PubMed ID: 11007800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ligand-binding domains of the thyroid hormone/retinoid receptor gene subfamily function in vivo to mediate heterodimerization, gene silencing, and transactivation.
    Qi JS; Desai-Yajnik V; Greene ME; Raaka BM; Samuels HH
    Mol Cell Biol; 1995 Mar; 15(3):1817-25. PubMed ID: 7862171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A movable and regulable inactivation function within the central region of a temperature-sensitive p53 mutant.
    Chuang JY; Lin CT; Wu CW; Lin YS
    J Biol Chem; 1995 Oct; 270(41):23899-902. PubMed ID: 7592577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
    Inga A; Resnick MA
    Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells.
    Deb S; Jackson CT; Subler MA; Martin DW
    J Virol; 1992 Oct; 66(10):6164-70. PubMed ID: 1356162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations in the interferon-sensitivity determining region of hepatitis C virus and transcriptional activity of the nonstructural region 5A protein.
    Fukuma T; Enomoto N; Marumo F; Sato C
    Hepatology; 1998 Oct; 28(4):1147-53. PubMed ID: 9755255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of the two-hybrid system to identify the domain of p53 involved in oligomerization.
    Iwabuchi K; Li B; Bartel P; Fields S
    Oncogene; 1993 Jun; 8(6):1693-6. PubMed ID: 8502489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A potential transcriptional activation element in the p53 protein.
    O'Rourke RW; Miller CW; Kato GJ; Simon KJ; Chen DL; Dang CV; Koeffler HP
    Oncogene; 1990 Dec; 5(12):1829-32. PubMed ID: 2284102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of Daxx interacting with p73, one of the p53 family, and its regulation of p53 activity by competitive interaction with PML.
    Kim EJ; Park JS; Um SJ
    Nucleic Acids Res; 2003 Sep; 31(18):5356-67. PubMed ID: 12954772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The retinoic acid receptor-beta 2 contains two separate cell-specific transactivation domains, at the N-terminus and in the ligand-binding domain.
    Folkers GE; van der Leede BJ; van der Saag PT
    Mol Endocrinol; 1993 Apr; 7(4):616-27. PubMed ID: 8389001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stimulation of polyomavirus DNA replication by wild-type p53 through the DNA-binding site.
    Kanda T; Segawa K; Ohuchi N; Mori S; Ito Y
    Mol Cell Biol; 1994 Apr; 14(4):2651-63. PubMed ID: 8139565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene.
    Chen J; Lin J; Levine AJ
    Mol Med; 1995 Jan; 1(2):142-52. PubMed ID: 8529093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Negative regulation of Rb expression by the p53 gene product.
    Shiio Y; Yamamoto T; Yamaguchi N
    Proc Natl Acad Sci U S A; 1992 Jun; 89(12):5206-10. PubMed ID: 1608930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Wild type p53 stimulates expression from the human multidrug resistance promoter in a p53-negative cell line.
    Goldsmith ME; Gudas JM; Schneider E; Cowan KH
    J Biol Chem; 1995 Jan; 270(4):1894-8. PubMed ID: 7829527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of the human hsp70 promoter by p53.
    Agoff SN; Hou J; Linzer DI; Wu B
    Science; 1993 Jan; 259(5091):84-7. PubMed ID: 8418500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inactive p53 mutants may enhance the transcriptional activity of wild-type p53.
    Zhang W; Shay JW; Deisseroth A
    Cancer Res; 1993 Oct; 53(20):4772-5. PubMed ID: 8402659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.